Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study

References

• Vaxman I, Gertz M. When to suspect a diagnosis of amyloidosis. Acta Haematol. 2020;143(4):304–311. doi: 10.1159/000506617.
   PubMed Web of Science ®Google Scholar
• Picken MM. The pathology of amyloidosis in classification: a review. Acta Haematol. 2020;143(4):322–334. doi: 10.1159/000506696.
   PubMed Web of Science ®Google Scholar
• Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–239. doi: 10.1080/07853890701842988.
   PubMed Web of Science ®Google Scholar
• Martinez-Naharro A, Baksi AJ, Hawkins PN, et al. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol. 2020;17(7):413–426. doi: 10.1038/s41569-020-0334-7.
   PubMed Web of Science ®Google Scholar
• Merlini G. CyBorD: stellar response rates in AL amyloidosis. Blood. 2012;119(19):4343–4345. doi: 10.1182/blood-2012-03-413112.
   PubMed Web of Science ®Google Scholar
• Falk RH, Alexander KM, Liao R, et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323–1341. doi: 10.1016/j.jacc.2016.06.053.
   PubMed Web of Science ®Google Scholar
• Ioannou A, Patel RK, Razvi Y, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis Over the course of 20 years. Circulation. 2022;146(22):1657–1670. doi: 10.1161/CIRCULATIONAHA.122.060852.
   PubMed Web of Science ®Google Scholar
• Jurcuţ R, Onciul S, Adam R, et al. Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging. 2020;21(8):833–844. doi: 10.1093/ehjci/jeaa063.
   PubMed Web of Science ®Google Scholar
• Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477–481. doi: 10.1016/j.ijcard.2016.04.030.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412. doi: 10.1161/CIRCULATIONAHA.116.021612.
   PubMed Web of Science ®Google Scholar
• Elliott PM, Anastasakis A, Authors/Task Force m., et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (ESC). Eur Heart J. 2014;35:2733–2779.
   PubMed Web of Science ®Google Scholar
• Paeng JC, Choi JY. Nuclear imaging for cardiac amyloidosis: bone scan, SPECT/CT, and amyloid-targeting PET. Nucl Med Mol Imaging. 2021;55(2):61–70. doi: 10.1007/s13139-020-00681-4.
   PubMed Web of Science ®Google Scholar
• Singh A, Musa TA, Treibel TA, et al. Sex differences in left ventricular remodelling, myocardial fibrosis and mortality after aortic valve replacement. Heart. 2019;105(23):1818–1824. doi: 10.1136/heartjnl-2019-314987.
   PubMed Web of Science ®Google Scholar
• Cohen OC, Sathyanath A, Petrie A, et al. Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis. Heart. 2022;108(20):1616–1622. doi: 10.1136/heartjnl-2021-320703.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Wechalekar A, Bird J, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol. 2015;168(2):207–218. doi: 10.1111/bjh.13156.
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28(1):1–39 e14. doi: 10.1016/j.echo.2014.10.003.
   PubMed Web of Science ®Google Scholar
• González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017;38(24):1895–1904. doi: 10.1093/eurheartj/ehx043.
   PubMed Web of Science ®Google Scholar
• Basset M, Milani P, Ferretti VV, et al. Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients. Clin Chem Lab Med. 2022;60(3):386–393. doi: 10.1515/cclm-2021-0912.
   PubMed Web of Science ®Google Scholar
• Ryšavá R. AL amyloidosis: advances in diagnostics and treatment. Nephrol Dial Transplant. 2019;34(9):1460–1466. doi: 10.1093/ndt/gfy291.
   PubMed Web of Science ®Google Scholar
• Nicol M, Baudet M, Brun S, et al. Diagnostic score of cardiac involvement in AL amyloidosis. Eur Heart J Cardiovasc Imag. 2020;21(5):542–548. doi: 10.1093/ehjci/jez180.
   PubMed Web of Science ®Google Scholar
• Lehrke S, Steen H, Kristen AV, et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid. 2009;16(4):187–195. doi: 10.3109/13506120903421538.
   PubMed Web of Science ®Google Scholar
• de Simone G, Gottdiener JS, Chinali M, et al. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the cardiovascular health study. Eur Heart J. 2008;29(6):741–747. doi: 10.1093/eurheartj/ehm605.
   PubMed Web of Science ®Google Scholar
• Griffin JM, Rosenthal JL, Grodin JL, et al. ATTR amyloidosis: current and emerging management strategies: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2021;3(4):488–505. doi: 10.1016/j.jaccao.2021.06.006.
   PubMedGoogle Scholar
• Pour-Ghaz I, Bath A, Kayali S, et al. A review of cardiac amyloidosis: presentation, diagnosis, and treatment. Curr Probl Cardiol. 2022;47(12):101366. doi: 10.1016/j.cpcardiol.2022.101366.
   PubMed Web of Science ®Google Scholar
• Jamal S, Kichloo A, Bailey B, et al. Clinical outcomes and disease burden in amyloidosis patients with and without atrial fibrillation-insight from the national inpatient sample database. J Innov Card Rhythm Manag. 2021;12(6):4542–4549. doi: 10.19102/icrm.2021.120605.
   PubMedGoogle Scholar
• Donnellan E, Wazni OM, Hanna M, et al. Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol. 2020;6(9):1118–1127. doi: 10.1016/j.jacep.2020.04.019.
   PubMedGoogle Scholar
• Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–953. doi: 10.1093/eurheartj/ehi825.
   PubMed Web of Science ®Google Scholar
• Xiao HB, Rizvi SA, McCrea D, et al. The association of chronic atrial fibrillation with right atrial dilatation and left ventricular dysfunction in the elderly. Med Sci Monit. 2004;10(9):CR516–20.
   PubMed Web of Science ®Google Scholar
• Binder C, Duca F, Binder T, et al. Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis. Clin Res Cardiol. 2021;110(4):532–543. doi: 10.1007/s00392-020-01698-7.
   PubMed Web of Science ®Google Scholar
• Berk JL, Keane J, Seldin DC, et al. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest. 2003;124(3):969–977. doi: 10.1378/chest.124.3.969.
   PubMed Web of Science ®Google Scholar
• Rigolli M, Anandabaskaran S, Christiansen JP, et al. Bias associated with left ventricular quantification by multimodality imaging: a systematic review and meta-analysis. Open Heart. 2016;3(1):e000388. doi: 10.1136/openhrt-2015-000388.
   PubMedGoogle Scholar
• Fujimiya T, Iwai-Takano M, Igarashi T, et al. Late gadolinium enhancement predicts improvement in global longitudinal strain after aortic valve replacement in aortic stenosis. Sci Rep. 2019;9(1):15688. doi: 10.1038/s41598-019-51930-2.
   PubMedGoogle Scholar